These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18231580)

  • 1. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.
    Thompson FM; Porter DW; Okitsu SL; Westerfeld N; Vogel D; Todryk S; Poulton I; Correa S; Hutchings C; Berthoud T; Dunachie S; Andrews L; Williams JL; Sinden R; Gilbert SC; Pluschke G; Zurbriggen R; Hill AV
    PLoS One; 2008 Jan; 3(1):e1493. PubMed ID: 18231580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
    Mensah VA; Gueye A; Ndiaye M; Edwards NJ; Wright D; Anagnostou NA; Syll M; Ndaw A; Abiola A; Bliss C; Gomis JF; Petersen I; Ogwang C; Dieye T; Viebig NK; Lawrie AM; Roberts R; Nicosia A; Faye B; Gaye O; Leroy O; Imoukhuede EB; Ewer KJ; Bejon P; Hill AV; Cisse B;
    PLoS One; 2016; 11(12):e0167951. PubMed ID: 27978537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
    Moorthy VS; Imoukhuede EB; Milligan P; Bojang K; Keating S; Kaye P; Pinder M; Gilbert SC; Walraven G; Greenwood BM; Hill AS
    PLoS Med; 2004 Nov; 1(2):e33. PubMed ID: 15526058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.
    Okitsu SL; Silvie O; Westerfeld N; Curcic M; Kammer AR; Mueller MS; Sauerwein RW; Robinson JA; Genton B; Mazier D; Zurbriggen R; Pluschke G
    PLoS One; 2007 Dec; 2(12):e1278. PubMed ID: 18060072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
    Dunachie SJ; Walther M; Epstein JE; Keating S; Berthoud T; Andrews L; Andersen RF; Bejon P; Goonetilleke N; Poulton I; Webster DP; Butcher G; Watkins K; Sinden RE; Levine GL; Richie TL; Schneider J; Kaslow D; Gilbert SC; Carucci DJ; Hill AV
    Infect Immun; 2006 Oct; 74(10):5933-42. PubMed ID: 16988273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study.
    Stanisic DI; Fink J; Mayer J; Coghill S; Gore L; Liu XQ; El-Deeb I; Rodriguez IB; Powell J; Willemsen NM; De SL; Ho MF; Hoffman SL; Gerrard J; Good MF
    BMC Med; 2018 Oct; 16(1):184. PubMed ID: 30293531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
    Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya.
    Sherwood JA; Copeland RS; Taylor KA; Abok K; Oloo AJ; Were JB; Strickland GT; Gordon DM; Ballou WR; Bales JD; Wirtz RA; Wittes J; Gross M; Que JU; Cryz SJ; Oster CN; Roberts CR; Sadoff JC
    Vaccine; 1996 Jun; 14(8):817-27. PubMed ID: 8817830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
    Hodgson SH; Ewer KJ; Bliss CM; Edwards NJ; Rampling T; Anagnostou NA; de Barra E; Havelock T; Bowyer G; Poulton ID; de Cassan S; Longley R; Illingworth JJ; Douglas AD; Mange PB; Collins KA; Roberts R; Gerry S; Berrie E; Moyle S; Colloca S; Cortese R; Sinden RE; Gilbert SC; Bejon P; Lawrie AM; Nicosia A; Faust SN; Hill AV
    J Infect Dis; 2015 Apr; 211(7):1076-86. PubMed ID: 25336730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites.
    Campo JJ; Aponte JJ; Skinner J; Nakajima R; Molina DM; Liang L; Sacarlal J; Alonso PL; Crompton PD; Felgner PL; Dobaño C
    Mol Cell Proteomics; 2015 Mar; 14(3):519-31. PubMed ID: 25547414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.
    Rampling T; Ewer KJ; Bowyer G; Bliss CM; Edwards NJ; Wright D; Payne RO; Venkatraman N; de Barra E; Snudden CM; Poulton ID; de Graaf H; Sukhtankar P; Roberts R; Ivinson K; Weltzin R; Rajkumar BY; Wille-Reece U; Lee CK; Ockenhouse CF; Sinden RE; Gerry S; Lawrie AM; Vekemans J; Morelle D; Lievens M; Ballou RW; Cooke GS; Faust SN; Gilbert S; Hill AV
    J Infect Dis; 2016 Sep; 214(5):772-81. PubMed ID: 27307573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
    Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
    Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.
    Richie TL; Charoenvit Y; Wang R; Epstein JE; Hedstrom RC; Kumar S; Luke TC; Freilich DA; Aguiar JC; Sacci JB; Sedegah M; Nosek RA; De La Vega P; Berzins MP; Majam VF; Abot EN; Ganeshan H; Richie NO; Banania JG; Baraceros MF; Geter TG; Mere R; Bebris L; Limbach K; Hickey BW; Lanar DE; Ng J; Shi M; Hobart PM; Norman JA; Soisson LA; Hollingdale MR; Rogers WO; Doolan DL; Hoffman SL
    Hum Vaccin Immunother; 2012 Nov; 8(11):1564-84. PubMed ID: 23151451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
    Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
    Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.
    Audran R; Lurati-Ruiz F; Genton B; Blythman HE; Ofori-Anyinam O; Reymond C; Corradin G; Spertini F
    PLoS One; 2009 Oct; 4(10):e7304. PubMed ID: 19798415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.
    Palacpac NM; Ntege E; Yeka A; Balikagala B; Suzuki N; Shirai H; Yagi M; Ito K; Fukushima W; Hirota Y; Nsereko C; Okada T; Kanoi BN; Tetsutani K; Arisue N; Itagaki S; Tougan T; Ishii KJ; Ueda S; Egwang TG; Horii T
    PLoS One; 2013; 8(5):e64073. PubMed ID: 23724021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men.
    Olotu A; Urbano V; Hamad A; Eka M; Chemba M; Nyakarungu E; Raso J; Eburi E; Mandumbi DO; Hergott D; Maas CD; Ayekaba MO; Milang DN; Rivas MR; Schindler T; Embon OM; Ruben AJ; Saverino E; Abebe Y; Kc N; James ER; Murshedkar T; Manoj A; Chakravarty S; Li M; Adams M; Schwabe C; Segura JL; Daubenberger C; Tanner M; Richie TL; Billingsley PF; Lee Sim BK; Abdulla S; Hoffman SL
    Am J Trop Med Hyg; 2018 Jan; 98(1):308-318. PubMed ID: 29141739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early whole blood transcriptional responses to radiation-attenuated Plasmodium falciparum sporozoite vaccination in malaria naïve and malaria pre-exposed adult volunteers.
    Duffy FJ; Du Y; Carnes J; Epstein JE; Hoffman SL; Abdulla S; Jongo S; Mpina M; Daubenberger C; Aitchison JD; Stuart K
    Malar J; 2021 Jul; 20(1):308. PubMed ID: 34243763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The march toward malaria vaccines.
    Hoffman SL; Vekemans J; Richie TL; Duffy PE
    Vaccine; 2015 Nov; 33 Suppl 4(Suppl 4):D13-23. PubMed ID: 26324116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens.
    Bettencourt P
    Front Immunol; 2020; 11():190. PubMed ID: 32153565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.